Intraocular lymphoma

Andrés J M Ferreri, Silvia Govi, Jose S Pulido

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Intraocular lymphoma (IOL) is a rare tumor characterized by the presence of lymphomatous cells infiltrating different ocular structures, associated or not with concomitant lesions in other areas of the central nervous system (CNS) or in distant organs. Some studies suggest an increasing incidence of IOL in the last few decades, with a peak of incidence in the fifth and sixth decades of age. IOL frequently resembles uveitis at presentation and is often misdiagnosed. Most patients with IOL will develop parenchymal brain lesions, and intraocular infiltration can be detected during clinical staging in patients presenting with primary CNS lymphoma. IOL can be stratified on the basis of the ocular structures infiltrated: the vitreoretinal form is the most common presentation of IOL, while lymphomas arising in the iris or the choroid are less common forms, with particular clinical and histopathological characteristics. Extent of disease evaluation is the same as proposed for primary CNS lymphoma. The prognosis of IOL remains relatively poor. Therapeutic options range from radiotherapy to chemotherapy, using CNS active drugs, like methotrexate and cytarabine. Encouraging results with intravitreous administration of rituximab and methotrexate and high-dose chemotherapy supported by autologous stem cell transplantation have been described. This chapter is focused on molecular, histopathological, clinical, and biological features, as well as management and prognosis of the different forms of IOL.

Original languageEnglish (US)
Title of host publicationLymphoma and Leukemia of the Nervous System
PublisherSpringer New York
Pages199-218
Number of pages20
ISBN (Print)9781441976680, 9781441976673
DOIs
StatePublished - Jan 1 2012

Fingerprint

Intraocular Lymphoma
Lymphoma
Central Nervous System
Methotrexate
Central Nervous System Agents
Drug Therapy
Choroid
Cytarabine
Incidence
Uveitis
Stem Cell Transplantation
Iris
Diagnostic Errors
Radiotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ferreri, A. J. M., Govi, S., & Pulido, J. S. (2012). Intraocular lymphoma. In Lymphoma and Leukemia of the Nervous System (pp. 199-218). Springer New York. https://doi.org/10.1007/9781441976680_12

Intraocular lymphoma. / Ferreri, Andrés J M; Govi, Silvia; Pulido, Jose S.

Lymphoma and Leukemia of the Nervous System. Springer New York, 2012. p. 199-218.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ferreri, AJM, Govi, S & Pulido, JS 2012, Intraocular lymphoma. in Lymphoma and Leukemia of the Nervous System. Springer New York, pp. 199-218. https://doi.org/10.1007/9781441976680_12
Ferreri AJM, Govi S, Pulido JS. Intraocular lymphoma. In Lymphoma and Leukemia of the Nervous System. Springer New York. 2012. p. 199-218 https://doi.org/10.1007/9781441976680_12
Ferreri, Andrés J M ; Govi, Silvia ; Pulido, Jose S. / Intraocular lymphoma. Lymphoma and Leukemia of the Nervous System. Springer New York, 2012. pp. 199-218
@inbook{e1acfa87f8dc452182cd83d43f762a4c,
title = "Intraocular lymphoma",
abstract = "Intraocular lymphoma (IOL) is a rare tumor characterized by the presence of lymphomatous cells infiltrating different ocular structures, associated or not with concomitant lesions in other areas of the central nervous system (CNS) or in distant organs. Some studies suggest an increasing incidence of IOL in the last few decades, with a peak of incidence in the fifth and sixth decades of age. IOL frequently resembles uveitis at presentation and is often misdiagnosed. Most patients with IOL will develop parenchymal brain lesions, and intraocular infiltration can be detected during clinical staging in patients presenting with primary CNS lymphoma. IOL can be stratified on the basis of the ocular structures infiltrated: the vitreoretinal form is the most common presentation of IOL, while lymphomas arising in the iris or the choroid are less common forms, with particular clinical and histopathological characteristics. Extent of disease evaluation is the same as proposed for primary CNS lymphoma. The prognosis of IOL remains relatively poor. Therapeutic options range from radiotherapy to chemotherapy, using CNS active drugs, like methotrexate and cytarabine. Encouraging results with intravitreous administration of rituximab and methotrexate and high-dose chemotherapy supported by autologous stem cell transplantation have been described. This chapter is focused on molecular, histopathological, clinical, and biological features, as well as management and prognosis of the different forms of IOL.",
author = "Ferreri, {Andr{\'e}s J M} and Silvia Govi and Pulido, {Jose S}",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/9781441976680_12",
language = "English (US)",
isbn = "9781441976680",
pages = "199--218",
booktitle = "Lymphoma and Leukemia of the Nervous System",
publisher = "Springer New York",

}

TY - CHAP

T1 - Intraocular lymphoma

AU - Ferreri, Andrés J M

AU - Govi, Silvia

AU - Pulido, Jose S

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Intraocular lymphoma (IOL) is a rare tumor characterized by the presence of lymphomatous cells infiltrating different ocular structures, associated or not with concomitant lesions in other areas of the central nervous system (CNS) or in distant organs. Some studies suggest an increasing incidence of IOL in the last few decades, with a peak of incidence in the fifth and sixth decades of age. IOL frequently resembles uveitis at presentation and is often misdiagnosed. Most patients with IOL will develop parenchymal brain lesions, and intraocular infiltration can be detected during clinical staging in patients presenting with primary CNS lymphoma. IOL can be stratified on the basis of the ocular structures infiltrated: the vitreoretinal form is the most common presentation of IOL, while lymphomas arising in the iris or the choroid are less common forms, with particular clinical and histopathological characteristics. Extent of disease evaluation is the same as proposed for primary CNS lymphoma. The prognosis of IOL remains relatively poor. Therapeutic options range from radiotherapy to chemotherapy, using CNS active drugs, like methotrexate and cytarabine. Encouraging results with intravitreous administration of rituximab and methotrexate and high-dose chemotherapy supported by autologous stem cell transplantation have been described. This chapter is focused on molecular, histopathological, clinical, and biological features, as well as management and prognosis of the different forms of IOL.

AB - Intraocular lymphoma (IOL) is a rare tumor characterized by the presence of lymphomatous cells infiltrating different ocular structures, associated or not with concomitant lesions in other areas of the central nervous system (CNS) or in distant organs. Some studies suggest an increasing incidence of IOL in the last few decades, with a peak of incidence in the fifth and sixth decades of age. IOL frequently resembles uveitis at presentation and is often misdiagnosed. Most patients with IOL will develop parenchymal brain lesions, and intraocular infiltration can be detected during clinical staging in patients presenting with primary CNS lymphoma. IOL can be stratified on the basis of the ocular structures infiltrated: the vitreoretinal form is the most common presentation of IOL, while lymphomas arising in the iris or the choroid are less common forms, with particular clinical and histopathological characteristics. Extent of disease evaluation is the same as proposed for primary CNS lymphoma. The prognosis of IOL remains relatively poor. Therapeutic options range from radiotherapy to chemotherapy, using CNS active drugs, like methotrexate and cytarabine. Encouraging results with intravitreous administration of rituximab and methotrexate and high-dose chemotherapy supported by autologous stem cell transplantation have been described. This chapter is focused on molecular, histopathological, clinical, and biological features, as well as management and prognosis of the different forms of IOL.

UR - http://www.scopus.com/inward/record.url?scp=84955083313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955083313&partnerID=8YFLogxK

U2 - 10.1007/9781441976680_12

DO - 10.1007/9781441976680_12

M3 - Chapter

AN - SCOPUS:84955083313

SN - 9781441976680

SN - 9781441976673

SP - 199

EP - 218

BT - Lymphoma and Leukemia of the Nervous System

PB - Springer New York

ER -